Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate Cancer Treatment
ReutersAug 22, 2025 4:04 AM
Aug 22 (Reuters) - Yantai Dongcheng Biochemicals Co Ltd 002675.SZ:
SAYS UNIT RECEIVES "STUDY MAY PROCEED LETTER" FROM U.S. FDA ON CLINICAL TRIAL OF AC-LNC1011 FOR PROSTATE CANCER TREATMENT
Source text
Further company coverage: 002675.SZ
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
FOMC August Meeting Minutes Commentary: Diverging Opinions, Rate Cut Optimism Outweighs Concerns, Your U.S. Stock Portfolio Remains Secure
TradingKey - On 21 August 2025, the Federal Open Market Committee (FOMC) released its latest meeting minutes, which revealed divisions among Fed officials due to a weakening job market and the impact of tariffs on inflation.TradingKey
an hour ago
Fed at a Crossroads: Powell Faces the Spotlight at Jackson Hole in a Moment of Fed Uncertainty
TradingKey - The annual Jackson Hole Symposium is currently underway, with Federal Reserve Chair Jerome Powell’s speech on Friday, August 22, drawing global attention. Amid growing internal divisions within the Fed and external pressure from the Trump administration to reshape its leadership, willTradingKey
3 hours ago
U.S. Manufacturing Revival and a Softening Dollar: Why Commodity ETFs Could Be the Next Investment Frontier
TradingKey - Contrasting sharply with the current surge in US AI&technology investments, traditional manufacturing is languishing, accompanied by widespread avoidance of commodities. Over the past 45 years, capital expenditure has consistently surged in technology-driven new economy sectors...TradingKey
4 hours ago
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed ChairTradingKey
Mon, Aug 18
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
